Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million
In This Article:
The move raises privacy concerns as the drugmaker takes control of the genetic data of millions of clients of the once-sizzling DNA-testing startup.
Oops, something went wrong
The move raises privacy concerns as the drugmaker takes control of the genetic data of millions of clients of the once-sizzling DNA-testing startup.